Select Language
Glycoprotein H&L
Product Inquiry
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Down Syndrome; Chronic Traumatic Encephalopathy; Alzheimer Disease; Parkinson Disease; Cognitive Dysfunction; Frontotemporal Dementia | Details |
| Gantenerumab | MAb-31; R-1450; RG-1450; R-04909832 | Phase 3 Clinical | Chugai Pharmaceutical Co Ltd | Alzheimer Disease; Dementia | Details |
| Valiltramiprosate | NRM-8499; ALZ-801; BLU-8499 | Phase 3 Clinical | Alzheon Inc | Alzheimer Disease | Details |
| Solanezumab | LY-2062430 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease; Dementia; Cognition Disorders | Details |
| Birtamimab | NEOD-001 | Phase 3 Clinical | Prothena | Immunoglobulin Light-chain Amyloidosis; Amyloidosis | Details |
| Remternetug | LY-3372993 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease; Dementia | Details |
| L-clausenamide | Phase 2 Clinical | Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd | Dementia; Cognitive Dysfunction; Memory Disorders | Details | |
| Crenezumab | MABT-5102-A; RG-7412; R-7412; RO-5490245 | Phase 2 Clinical | Ac Immune Sa | Alzheimer Disease | Details |
| 11C-BF-227 | 11C-BF-227; [11C]BF-227 | Phase 2 Clinical | Tohoku University | Diagnostic agents | Details |
| Pittsburgh Compound B | [11C]PIB; [11C]6-OH-BTA-1; 11C-PIB | Phase 2 Clinical | The University Of Utah, University Of Pittsburgh, Ge Healthcare, Uppsala Universitet | Ovarian Neoplasms; Brain Concussion; Breast Neoplasms; Alzheimer Disease; Alcoholism; Dementia; Parkinson Disease | Details |
| CT-1812 | CT-1812; SV-119 | Phase 2 Clinical | Cogrx | Alzheimer Disease; Cognitive Dysfunction; Lewy Body Disease; Macular Degeneration | Details |
| [18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
| Edonerpic | T-817 MA | Phase 2 Clinical | Toyama Chemical Co Ltd, Fujifilm Group | Alzheimer Disease; Cognitive Dysfunction; Hepatic Insufficiency | Details |
| ABvac-40 | ABvac-40 | Phase 2 Clinical | Araclon Biotech Sl | Alzheimer Disease; Cognitive Dysfunction | Details |
| PK-051 | PK051; PK-051 | Phase 2 Clinical | PharmaKure Ltd | Alzheimer Disease; Cognitive Dysfunction | Details |
| PRI-002 | RD-2; PRI-002 | Phase 2 Clinical | PRInnovation GmbH, Priavoid | Alzheimer Disease; Cognitive Dysfunction | Details |
| 18F-92 | 18F-92 | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Alzheimer Disease | Details |
| SHR-1707 | SHR-1707 | Phase 2 Clinical | Alzheimer Disease | Details | |
| [18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
| AD-35 | AD-35 | Phase 2 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Alzheimer Disease | Details |
| Trontinemab | RO-7126209; RG-6102 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
| APH-1105 | APH-1105 | Phase 2 Clinical | Aphios | Dementia; Alzheimer Disease | Details |
| RIV-1061-IR | RIV-1061; RIV-1061-IR | Phase 1 Clinical | Revivo Therapeutics | Alzheimer Disease; Cognition Disorders | Details |
| A ß antibody Fab | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
| RQ-9 | AAT-009; RQ-9; RQ-00000009 | Phase 1 Clinical | Pfizer Inc | Dementia | Details |
| MDR-1339 | DBT-1339; MDR-1339 | Phase 1 Clinical | Medifron | Alzheimer Disease | Details |
| AV-1959D | AV 1959D; AV-1959D | Phase 1 Clinical | Institute For Molecular Medicine, University Of California, Flinders University | Alzheimer Disease | Details |
| ALZ-101 | ALZ-101 | Phase 1 Clinical | Alzinova AB | Alzheimer Disease; Dementia | Details |
| PRX-012 | PRX-012 | Phase 1 Clinical | Prothena | Alzheimer Disease | Details |
| PMN-310 | huPMN-310; PMN-310 | Phase 1 Clinical | ProMIS Neurosciences Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Multiple System Atrophy | Details |
| CM-383 | CM383; CM-383 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Cognitive Dysfunction; Alzheimer Disease | Details |
| RP-902 | RP902; RP-902 | Phase 1 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Alzheimer Disease | Details |
| ACU-193 | ACU-193; ACU193 | Phase 1 Clinical | Acumen Pharmaceuticals Inc | Alzheimer Disease | Details |
| OAB-14 | OAB-14 | Phase 1 Clinical | Shenyang Pharmaceutical University | Alzheimer Disease | Details |
| ALN-APP | Phase 1 Clinical | Sirna Therapeutics Inc | Cerebral Amyloid Angiopathy; Spinocerebellar Degenerations; Alzheimer Disease; Neurodegenerative Diseases | Details | |
| BEY-2153 | BEY-2153 | Phase 1 Clinical | Beyondbio Inc | Alzheimer Disease | Details |
| Abeta42 antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
| Anatabine citrate | RCP-006 | Clinical | Rock Creek, Roskamp Institute | Thyroiditis, Autoimmune; Smoking Cessation; Tobacco Use Disorder; Alzheimer Disease; Inflammation | Details |
| 123I-ABC-577 | 123I-ABC-577 | Clinical | Nihon Medi-Physics Co Ltd | Diagnostic agents | Details |
| Tarenflurbil spraygel (MIKA Pharma) | Clinical | Galen Ltd, Mika Pharma Gmbh | Pain; Arthritis, Rheumatoid; Skin Diseases; Inflammation; Dermatitis, Atopic | Details | |
| Procaine Hydrochloride/Vitamin B6/Inositol | Details | ||||
| Inositol/Vitamin B1/Vitamin B2 | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Donanemab | LY-3002813-IV; LY-3002813-SC; LY-3002813 | Approved | Eli Lilly And Company | Kisunla | United States | Alzheimer Disease | Eli Lilly And Company | 2024-07-02 | Neurocognitive Disorders; Brain Diseases; Dementia; Tauopathies; Alzheimer Disease; Cognitive Dysfunction; Nervous System Diseases; Central Nervous System Diseases; Neurodegenerative Diseases; Mental Disorders; Cognition Disorders | Details |
| Sodium Oligomannurarate | GV-971; 971 | Approved | Ocean University Of China, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 九期一 | Mainland China | Alzheimer Disease | Shanghai Greenvalley Pharmaceutical Co Ltd | 2019-11-02 | Parkinson Disease; Cognitive Dysfunction; Alzheimer Disease | Details |
| Flutemetamol (18F) | AH-110690; GE-067; 18F-GE067 | Approved | Ge Healthcare | Vizamyl | United States | Contrast agents | Ge Healthcare | 2013-10-25 | Atherosclerosis; Cardiomyopathies; Contrast agents; Breast Neoplasms; Cognitive Dysfunction; Alzheimer Disease; Dementia; Diagnostic agents; Hydrocephalus, Normal Pressure; Cognition Disorders | Details |
| Inositol | 4L6452S749 | Approved | Nicosit | Anovulation; Depression; Anxiety; Diabetic Neuropathies; Insulin Resistance; Polycystic Ovary Syndrome; Glucose Intolerance; Infant, Newborn, Diseases; Bronchopulmonary Dysplasia; Metabolic Diseases; Lung Neoplasms; Retinopathy of Prematurity; Precancerous Conditions; Premature Birth; Hyperandrogenism; Carcinoma, Non-Small-Cell Lung | Details | |||||
| Immune globulin 10% (Grifols) | KIg-10; TAL-05-0002 | Approved | Bayer AG | Gamunex, Gammaked | United States | Purpura, Thrombocytopenic, Idiopathic; Immunologic Deficiency Syndromes; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | null | 2003-08-27 | Postural Orthostatic Tachycardia Syndrome; Kidney Failure, Chronic; Immunologic Deficiency Syndromes; Corneal Neovascularization; Common Variable Immunodeficiency; Muscular Diseases; Neuralgia; Reflex Sympathetic Dystrophy; Obsessive-Compulsive Disorder; Severe Combined Immunodeficiency; Primary Immunodeficiency Diseases; Autoimmune Diseases; Anxiety Disorders; Coronavirus Disease 2019 (COVID-19); Agammaglobulinemia; Wiskott-Aldrich Syndrome; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Tibial Fractures; Myasthenia Gravis | Details |
| Florapronol (18F) | 18F-FC-119S; 18F-FC-119(S) | Approved | Korea Institute Of Radiological And Medical Sciences, Futurechem | Alzavue | Alzheimer Disease | Details | ||||
| Aducanumab | BIIB-037; NI-10; BART | Approved | Neurimmune Ag | ADUHELM | United States | Alzheimer Disease | Biogen Inc | 2021-06-07 | Cognitive Dysfunction; Dementia; Alzheimer Disease | Details |
| L-Lysine hydrochloride/Cyanocobalamin/Inositol | Approved | 兴邦 | Malnutrition | Details | ||||||
| Immune Globulin Subcutaneous (Human) (Octapharma) | Approved | Octapharma | Cutaquig, Octanorm, Gammanorm | United States | Immunologic Deficiency Syndromes | null | 2018-08-02 | Primary Immunodeficiency Diseases; Dermatomyositis; Immunologic Deficiency Syndromes | Details | |
| Florbetaben (18F) | MNI-815; AV-1; ZK-6013443; BAY-949172; 18F-AV-1; 18F-AV1/ZK; AV-1/ZK; BAY 94-9172; UNII-TLA7312TOI | Approved | Piramal | Neuraceq, 欧韦宁 | EU | Alzheimer Disease | Life Radiopharma Berlin Gmbh | 2014-02-20 | Supranuclear Palsy, Progressive; Down Syndrome; Hyponatremia; Immunoglobulin Light-chain Amyloidosis; Contrast agents; Amyloidosis; Alzheimer Disease; Dementia | Details |
| Lecanemab | BAN-2401 | Approved | Bioarctic Neuroscience | Leqembi, LEQEMBI, 乐意保 | United States | Alzheimer Disease | Eisai Inc | 2023-01-06 | Alzheimer Disease; Dementia; Cognitive Dysfunction | Details |
| Florbetapir(18F) | MNI-798; AV-45 | Approved | Eli Lilly And Company | Amyvid | United States | Spasms, Infantile; Rheumatic Diseases; Respiration Disorders; Multiple Sclerosis; Eye Diseases; Collagen Diseases; Skin Diseases; Hypersensitivity | Avid Radiopharmaceuticals Inc | 2012-04-06 | Amyloidosis; Hypersensitivity; Frontotemporal Dementia; Neurodegenerative Diseases; Collagen Diseases; Eye Diseases; Lewy Body Disease; Diagnostic agents; Parkinson Disease; Respiration Disorders; Alzheimer Disease; Rheumatic Diseases; Cognitive Dysfunction; Contrast agents; Spasms, Infantile; Skin Diseases; Multiple Sclerosis; Glioblastoma | Details |
- Product Inquiry
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland